Smiths Medical Announces Launch of Portex® EchoGlo® Peripheral Nerve Block Portfolio

The Portex^® EchoGlo^® needle has been engineered for echogenic brightness under ultrasound even at extreme angles, which can enhance visualization and accuracy in delivering medication. This proprietary technology helps clinicians to confidently place local anesthetic, which may reduce post-operative dependency on opioids¹.

“Smiths Medical is proud to offer EchoGlo^® nerve block needles as part of our patient to pump solution. Combining the echogenic brightness of EchoGlo^® products with our CADD^® pump portfolio provides a full solution for our clinicians and patients,” said Jaimie Mattson, Senior Director, Global Product Management at Smiths Medical.

The launch of the full EchoGlo^® portfolio enables Smiths Medical to offer clinicians more solutions to treat their patients safely and effectively.

For more information about our new EchoGlo^® portfolio visit https://www.smiths-medical.com/products/pain-management/peripheral-nerve-block--plexus-anesthesia/echoglo-peripheral-nerve-block-needle.

¹Valdivieso, Ronald MD. “Peripheral Nerve Blocks.” Anesthesia Secrets, 4^th Ed., 2011, pp.466-471

About Smiths Medical

A leading supplier of specialized medical devices and equipment for global markets, focusing on the medication delivery, vital care and safety devices market segments. For more information, visit www.smiths-medical.com.

About Smiths Group

A global technology company that has been operating for nearly 170 years, delivering products and services for the medical technology, security & defence, general industrial, energy and space & commercial aerospace markets worldwide. Smiths Group plc employs c. 23,000 colleagues in over 50 countries and is listed on the London Stock Exchange. For more information visit www.smiths.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201214005094/en/